PET引导的弥漫大B细胞淋巴瘤CAR-T候选者早期识别多学科专家共识
该多学科专家共识探讨如何将[¹⁸F]FDG PET/CT系统整合入弥漫大B细胞淋巴瘤临床路径,以早期识别可能受益于CAR-T治疗的患者。共识认为PET/CT是DLBCL管理的核心生物标志物,基线代谢肿瘤体积等定量指标可改善风险分层, interim PET的Deauville评分和SUVmax变化有助于早期识别高危或难治患者,治疗结束PET对疗效评估和治疗决策仍至关重要。
要点
- 基线PET定量指标如代谢肿瘤体积可超越传统指标改善风险分层
- 中期PET的Deauville评分和SUVmax变化有助于早期识别高危或难治患者
- 需标准化采集、报告和解读以增强可重复性和临床整合
核心结论
- PET/CT应被视为DLBCL管理的核心生物标志物,可早期识别高危患者并促进及时CAR-T转诊。
- 协调一致的多学科实施对于优化结局和改善潜在治愈性治疗的可及性至关重要。
研究设计与样本
- 由核医学医师和血液科医师组成的多学科专家组,基于当前文献、国际指南和专家讨论开展结构化共识流程。
- 在多次会议上评估关键临床场景和声明,以明确PET/CT在基线、中期和治疗结束阶段的作用。
主要发现
- PET/CT在整个疾病过程中提供关键预后信息。
- 基线定量指标(如代谢肿瘤体积)可超越传统指标改善风险分层。
- 中期PET尤其使用Deauville评分和最大标准化摄取值变化,能够早期识别高危或难治患者。
- 治疗结束PET对疗效评估和治疗决策仍至关重要。
关键数值与推荐
- 基线定量指标如代谢肿瘤体积可改善风险分层。
- 中期PET使用Deauville评分和SUVmax变化识别高危或难治患者。
- 治疗结束PET用于疗效评估和治疗决策。
- 标准化采集、报告和解读是增强可重复性和临床整合的必要条件。
临床怎么用
- 将PET/CT系统整合入DLBCL临床路径,用于基线、中期和治疗结束阶段的评估。
- 利用基线代谢肿瘤体积等定量指标和中期Deauville评分及SUVmax变化早期识别高危或难治患者,及时转诊CAR-T。
- 标准化PET采集、报告和解读以增强可重复性和临床整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This expert consensus aims to define how 2-deoxy-2-[18 F]-fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) can be systematically integrated into clinical pathways for early identification of diffuse large B-cell lymphoma (DLBCL) patients who may benefit from chimeric antigen receptor T-cell (CAR-T) therapy. The main research question is how PET-derived parameters and timing can optimize risk stratification and guide timely referral for advanced therapies. METHODS: A multidisciplinary panel of nuclear medicine physicians and hematologists conducted a structured consensus process based on current literature, international guidelines, and expert discussion. Key clinical scenarios and statements were evaluated across multiple meetings to assess the role of PET/CT at baseline, interim, and end-of-treatment stages. RESULTS: PET/CT provides critical prognostic information throughout the disease course. Baseline quantitative metrics (e.g., metabolic tumor volume) improve risk stratification beyond conventional indices. Interim PET, particularly using Deauville score and the change in the maximum standardized uptake value, enables early identification of high-risk or refractory patients. End-of-treatment PET remains essential for response assessment and therapeutic decision-making. Standardization of acquisition, reporting, and interpretation is necessary to enhance reproducibility and clinical integration. CONCLUSION: PET/CT should be considered a central biomarker in DLBCL management, enabling earlier identification of high-risk patients and facilitating timely CAR-T referral. Harmonized, multidisciplinary implementation is essential to optimize outcomes and improve access to potentially curative therapies.
引用
- Guerra L, Albano D, Angelillo P, et al. PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus. Eur J Nucl Med Mol Imaging. 2026. PMID: 42360330. doi:10.1007/s00259-026-07999-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。